Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Sep;1(1):a007252.
doi: 10.1101/cshperspect.a007252.

Vaccine design for CD8 T lymphocyte responses

Richard A Koup  1 , Daniel C Douek
Affiliations
Review

Vaccine design for CD8 T lymphocyte responses

Richard A Koup et al. Cold Spring Harb Perspect Med. 2011 Sep.

Abstract

Vaccines are arguably the most powerful medical intervention in the fight against infectious diseases. The enormity of the global human immunodeficiency virus type 1 (HIV)/acquired immunodeficiency syndrome (AIDS) pandemic makes the development of an AIDS vaccine a scientific and humanitarian priority. Research on vaccines that induce T-cell immunity has dominated much of the recent development effort, mostly because of disappointing efforts to induce neutralizing antibodies through vaccination. Whereas T cells are known to limit HIV and other virus infections after infection, their role in protection against initial infection is much less clear. In this article, we will review the rationale behind a T-cell-based vaccine approach, provide an overview of the methods and platforms that are being applied, and discuss the impact of recent vaccine trial results on the future direction of T-cell vaccine research.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Attributes of CD8 T cells associated with virus control in infected individuals. These characteristics are thought important to emulate in the response elicited by a vaccine. The role of CD8 T cells should be viewed in the light of the roles of CD4 T cells and B cells.
See this image and copyright information in PMC

References

    1. Abdulhaqq SA, Weiner DB 2008. DNA vaccines: Developing new strategies to enhance immune responses. Immunol Res 42: 219–232 - PubMed
    1. Abrahams MR, Anderson JA, Giorgi EE, Seoighe C, Mlisana K, Ping LH, Athreya GS, Treurnicht FK, Keele BF, Wood N, et al. 2009. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 83: 3556–3567 - PMC - PubMed
    1. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, et al. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 77: 2081–2092 - PMC - PubMed
    1. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, Robbins GK, Basgoz NO, Stone DR, Cohen DE, et al. 2007. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS One 2: e321 10.1371/journal.pone.0000321 - DOI - PMC - PubMed
    1. Baig J, Levy DB, McKay PF, Schmitz JE, Santra S, Subbramanian RA, Kuroda MJ, Lifton MA, Gorgone DA, Wyatt LS, et al. 2002. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J Virol 76: 11484–11490 - PMC - PubMed